Bolt Biotherapeutics’ Gujrathi gets 72,766 common shares
The merger terms provided 1.6413 BOLT common shares or common-stock equivalents per Prana common share; no cash purchase price was paid for Series D Preferred.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Sheila Gujrathi, Bolt Biotherapeutics' Chief Strategy Officer and a director, reported direct receipt of 72,766 common shares and 2,763.833 Series D Preferred shares when her Prana Therapies shares converted at the merger closing on October 23, 2026. SilverArc Private Fund I, L.P.'s Prana holdings converted into 13,055 common shares and 495.874 Series D Preferred shares; Gujrathi disclaims beneficial ownership of the fund's securities except to the extent of any pecuniary interest. Each Series D Preferred share is convertible into 1,000 common shares, subject to conditions including requisite stockholder approval.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Series D Preferred Stock F4, F1, F2 | 2,763.833 | -- | -- |
| Other | Series D Preferred Stock F4, F1, F2, F3 | 495.874 | -- | -- |
| Grant/Award | Common Stock F1, F2 | 72,766 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1, F2, F3 | 13,055 | $0.00 | $0.00 |
Footnotes (4)
- F1. Received in exchange for shares of common stock of Prana Therapies, Inc. ("Prana") pursuant to the Agreement and Plan of Merger dated October 23, 2026 (the "Merger Agreement") by and among the Issuer, Prana, Prince Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub I"), Prince Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Merger Sub II"). Each outstanding share of Prana common stock was converted into the right to receive 1.6413 shares of the Issuer's common stock or common-stock equivalents, consisting of Issuer's common stock and Series D Convertible Preferred Stock ("Series D Preferred") convertible at a rate of 1,000 shares of Issuer's common stock per share of Series D Preferred. No cash purchase price was paid for the Series D Preferred received as merger consideration.
- F2. Upon closing of the merger on October 23, 2026, Prana shares held directly by the Reporting Person converted into 72,766 shares of Issuer's common stock and 2,763.833 shares of Series D Preferred. Prana shares held by SilverArc Private Fund I, L.P. converted into 13,055 shares of Issuer's common stock and 495.874 shares of Series D Preferred. The 495.874 shares of Series D Preferred constitute merger consideration
- F3. The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of the Non-Derivative and Derivative securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.
- F4. Each share of Series D Preferred is convertible into 1,000 shares of the Issuer's common stock, subject to the conditions set forth in the Certificate of Designation, including receipt of the requisite stockholder approval. The Series D Preferred has no expiration date.
Key Figures
Key Terms
Series D Preferred financial
common-stock equivalents financial
Certificate of Designation technical
pecuniary interest financial
Agreement and Plan of Merger technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.